Samil PharmaceuticalLtd 과거 수익 실적

과거 기준 확인 0/6

Samil PharmaceuticalLtd의 수입은 연평균 -4.6%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 7.8%의 비율로 증가했습니다. 매출은 연평균 13.8%의 비율로 증가해 왔습니다.

주요 정보

-4.6%

수익 성장률

-4.0%

EPS 성장률

Pharmaceuticals 산업 성장	11.3%
매출 성장률	13.8%
자기자본 수익률	-0.7%
순이익	-0.6%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Mar 21

Recent updates

Some Samil Pharmaceutical Co.,Ltd (KRX:000520) Shareholders Look For Exit As Shares Take 27% Pounding

Nov 18

Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking

Sep 13

We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt

Sep 11

Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking

Jul 29

Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?

May 24

There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Mar 30

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Mar 21

Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Apr 01

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Mar 11

Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

Feb 15

Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

Jan 20

Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Dec 24

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

Dec 09

What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Nov 18

수익 및 비용 분석

Samil PharmaceuticalLtd 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

KOSE:A000520 수익, 비용 및 수입 (KRW Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	212,424	-1,174	67,229	5,828
30 Jun 24	210,733	-1,155	64,532	5,913
31 Mar 24	204,905	-786	61,461	5,870
31 Dec 23	196,346	1,664	59,962	5,601
30 Sep 23	189,293	2,600	59,638	5,249
30 Jun 23	183,060	1,336	59,752	4,342
31 Mar 23	179,566	343	58,907	3,553
31 Dec 22	179,676	-28	58,519	2,907
30 Sep 22	170,510	-4,989	55,364	2,359
30 Jun 22	158,910	-4,740	51,226	2,617
31 Mar 22	147,877	-5,619	48,047	2,948
31 Dec 21	134,247	-5,347	43,763	2,971
30 Sep 21	129,974	-2,761	41,634	3,007
30 Jun 21	127,287	-1,327	40,709	3,007
31 Mar 21	122,793	132	38,960	2,593
31 Dec 20	122,999	1,341	37,989	3,007
30 Sep 20	123,114	940	36,510	3,185
30 Jun 20	122,308	729	37,087	2,847
31 Mar 20	123,102	1,429	37,461	3,183
31 Dec 19	121,107	786	37,453	3,060
30 Sep 19	114,364	-1,251	37,792	3,060
30 Jun 19	107,856	-3,368	37,017	2,969
31 Mar 19	102,805	-6,461	37,498	2,619
31 Dec 18	94,600	-8,563	37,373	2,182
30 Sep 18	96,882	-5,165	37,580	2,026
30 Jun 18	94,916	-4,605	36,925	2,087
31 Mar 18	92,286	-2,797	36,168	1,987
31 Dec 17	92,038	-1,267	36,734	1,961
30 Sep 17	90,658	-1,434	35,792	1,938
30 Jun 17	92,118	898	35,357	1,605
31 Mar 17	94,685	948	35,882	1,447
31 Dec 16	96,758	887	35,667	1,254
30 Sep 16	94,010	306	35,309	1,047
30 Jun 16	92,625	140	34,909	1,136
31 Mar 16	88,656	553	33,503	1,121
31 Dec 15	88,136	588	33,688	1,119
30 Sep 15	85,795	-2,986	35,250	1,457
30 Jun 15	85,439	-6,170	36,903	1,831
31 Mar 15	85,849	-10,179	39,225	2,477
31 Dec 14	85,461	-11,190	39,011	2,790
30 Sep 14	87,683	1,148	37,998	2,841
30 Jun 14	87,545	3,601	37,061	2,126
31 Mar 14	89,207	7,191	34,562	2,182
31 Dec 13	89,229	7,930	34,631	2,046

양질의 수익: A000520 은(는) 현재 수익성이 없습니다.

이익 마진 증가: A000520 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: A000520 은(는) 수익성이 없으며 지난 5년 동안 연간 4.6% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 A000520 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: A000520 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 20.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: A000520 현재 수익성이 없기 때문에 마이너스 자본 수익률( -0.67% )을 갖습니다.

Samil PharmaceuticalLtd 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings released: ₩39.00 loss per share (vs ₩46.00 loss in 3Q 2023)

First quarter 2024 earnings released: ₩118 loss per share (vs ₩55.00 profit in 1Q 2023)

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Full year 2023 earnings released: EPS: ₩116 (vs ₩2.00 loss in FY 2022)

First quarter 2023 earnings released: EPS: ₩55.00 (vs ₩27.00 in 1Q 2022)

Full year 2022 earnings released: ₩2.00 loss per share (vs ₩425 loss in FY 2021)

Recent updates

Third quarter 2024 earnings released: ₩39.00 loss per share (vs ₩46.00 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Some Samil Pharmaceutical Co.,Ltd (KRX:000520) Shareholders Look For Exit As Shares Take 27% Pounding

Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking

We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt

New minor risk - Share price stability

Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking

Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?

First quarter 2024 earnings released: ₩118 loss per share (vs ₩55.00 profit in 1Q 2023)

There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Full year 2023 earnings released: EPS: ₩116 (vs ₩2.00 loss in FY 2022)

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 24%

New minor risk - Shareholder dilution

First quarter 2023 earnings released: EPS: ₩55.00 (vs ₩27.00 in 1Q 2022)

Full year 2022 earnings released: ₩2.00 loss per share (vs ₩425 loss in FY 2021)

Upcoming dividend of ₩80.00 per share

Samil Pharmaceutical Co.,Ltd announced that it has received KRW 4 billion in funding

Samil Pharmaceutical Co.,Ltd announced that it expects to receive KRW 5 billion in funding

First quarter 2022 earnings released: EPS: ₩27.00 (vs ₩49.00 in 1Q 2021)

Upcoming dividend of ₩75.00 per share

Samil Pharmaceutical Co.,Ltd announced that it has received KRW 35 billion in funding from a group of investors

Samil Pharmaceutical Co.,Ltd announced that it expects to receive KRW 35 billion in funding from a group of investors

Samil Pharmaceutical Co.,Ltd (KOSE:A000520) announces an Equity Buyback for KRW 500 million worth of its shares.

Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Full year 2020 earnings released: EPS ₩219 (vs ₩129 in FY 2019)

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Samil Pharmaceutical Co.,Ltd, Annual General Meeting, Mar 19, 2021

Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

New 90-day low: ₩19,950

Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

New 90-day low: ₩20,050

Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Upcoming Dividend of ₩150 Per Share

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

New 90-day low: ₩20,300

What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Third quarter 2020 earnings released: ₩39.00 loss per share

New 90-day high - ₩24,400

New 90-day high - ₩23,650

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기